Гемотологические оосложнения таргетной терапии местнораспростронненого рака почки и пути его коррекции

Аннотация

The article presents the results of treatment of patients received targeted therapy with Sunitinib on me-tastasis of renal cancer to the lymph nodes. The total number of patients was 38. Male 21 (55.2%), female 17 (44.7%), ratio 1.2: 1. The average age is 50 ± 2.4 years. The complications associated with the use of angiogenesis blockers and tyrosine kinase inhibitors have been analyzed. The main undesirable side effects against the background of Sunitinib therapy, from the side of the blood indices: neutropenia, hypophosphatemia, lymphopenia, anemia, thrombocytopenia, increasing of the serum creatinine and total cholesterol. The results of treatment allow us to recommend the use of sunitinib for the treatment of patients with me-tastases in the lymph nodes of renal cancer, emphasizing the need for timely prevention of complications of this treatment